Many believe cancer immunotherapy is a guaranteed solution, but the reality in oncology is that strong responses only occur in a minority of patients. This highlights the need for personalized medicine approaches, focusing on precision oncology to improve cancer treatment outcomes, according to a medical oncologist. Further research in immunology is crucial.

Why do only 1 in 5 cancer patients respond to immunotherapy?
In this critical episode, Dr. Dino Prato, founder of Envita Medical Centers, reveals the deeper science behind why PD-1 and PD-L1 checkpoint inhibitors often fail — and how precision immunotherapy may dramatically change that outcome.

Checkpoint inhibitors are powerful, but for most patients, the response doesn’t last — or never starts. This doesn’t mean immunotherapy is broken. It means most patients aren’t receiving care that’s truly customized to their tumor’s immune environment.

🎯 What You’ll Learn:

• Why “cold tumors” block T cells from doing their job
• How spatial biology, immune profiling, and antigen mapping help personalize immunotherapy
• What immune exhaustion looks like — and how to reverse it
• Why combining genomics, transcriptomics, and natural killer (NK) cell therapy can improve tumor visibility
• How precision immunotherapy is helping patients aim beyond temporary response — and toward long-term remission
  
  

In our clinical experience, using N-of-1 mapping has enabled more durable responses by removing guesswork and guiding treatment with real-time immune data.

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at: https://www.scirp.org/journal/paperinformation?paperid=132493